Given the increased role of LZTR1 as a RAS-regulator in hematologic cancers, this dual function may explain why A146 mutations are enriched in hematologic malignancies but are largely absent from pancreatic and many other epithelial cancers1. The gene discussed is LZTR1; the disease is hematologic disorder.